Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Clinical trial NCT02312622 · COMPLETED

Trial details

NCT number: NCT02312622
Sponsor: Joel Neal
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Stage IV Non-small Cell Lung Cancer (NSCLC)Recurrent Non-small Cell Lung Cancer (NSCLC)Extensive-stage Small Cell Lung Cancer (SCLC)Recurrent Small Cell Lung Cancer (SCLC)Tumors Metastatic to Brain Metastatic Breast Cancer (mBC)

Start date: 2015-08-01
Primary completion: 2018-09-08
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.